GILD · News · 20260922N

HIV Prevention Access Pressure

GILEAD SCIENCES, INC. · 2026-09-22 · Importance 31 · Surprise 42

Gilead is expanding HIV prevention access through royalty-free licenses for lenacapavir. It also signed a new access agreement with the Pan American Health Organization, broadening potential availability across the Americas. The initiatives could support adoption of lenacapavir in HIV prevention markets while increasing access-related pressure on commercial pricing and royalties.